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Abstract
Purpose The anticoagulation response to vitamin K
antagonists is characterised by high inter-individual
variability. The impact of single nucleotide polymor-
phisms (SNPs) in several genes of enzymes involved in
the vitamin K cycle on phenprocoumon dose variability
and phenprocoumon plasma concentrations is still under
investigation.
Methods We assessed the influence of VKORC1 c.-
1639G>A, CYP2C9*2, CYP2C9*3, CYP4F2 c.1297G>A,
CALU c.*4A>G, EPHX1 c.337T>C, GGCX c.214+597G>A,
F7 c.-402G>A, F7 c.-401G>T, PROC c.-228C>Tand PROC
c.-215G>A along with clinical and demographic parameters
on steady-state phenprocoumon therapy in 75 patients. A
prediction model was developed for total phenprocoumon
plasma concentrations and daily phenprocoumon doses
required for therapeutic anticoagulation.
Results The VKORC1 c.-1639 genotype was the main
predictor of the phenprocoumon daily dose (adjusted
R
2=37.6%) and the total phenprocoumon concentration
(adjusted R
2=38.3%). CYP2C9 affected the phenprocou-
mon concentration, but not the dose requirements. SNPs in
the other genes of the vitamin K cycle, concomitant
medication, nicotine use and alcohol consumption did not
predict phenprocoumon concentrations and phenprocou-
mon dose requirements in a multiple linear regression
model. Phenprocoumon concentrations were predicted by
VKORC1 c.-1639, CYP2C9 genotype, age and BMI. The
final prediction model for the daily phenprocoumon dose
requirements comprised VKORC1 c.-1639 genotype, age
and height accounting for 48.6% of the inter-individual
variability.
Conclusions A rough prediction of phenprocoumon main-
tenance doses can be achieved by a limited set of
parameters (VKORC1, age, height). The investigated SNPs
in CYP4F2, CALU, EPHX1, GGCX, F7, and PROC did not
improve the predictive value of a pharmacogenetic-based
dosing equation for phenprocoumon.
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Introduction
Coumarins are effective for the primary and secondary
prevention of venous thrombosis and arterial thromboem-
bolism; however, they are one of the most common causes
of serious adverse drug events [1, 2]. Therapy with
coumarins is characterised by a narrow therapeutic range,
high inter-individual differences in dose response, and a
considerable risk of a wide range of clinically relevant drug
interactions. Inappropriate dosing of coumarins is associat-
ed with a substantial risk of both recurrent thromboembo-
lism from under-anticoagulation and bleeding from
overanticoagulation [3, 4].
A number of demographic, clinical and genetic factors
have been shown to influence the anticoagulant effect of
coumarins [4]. Furthermore, factors such as compliance,
intercurrent diseases/infections and lifestyle factors, including
physical activity and diet, may influence dose demands of
coumarins. Coumarins exert their anticoagulant effects by
inhibitionofthevitaminKepoxidereductasecomplexsubunit
1(VKORC1),whichconvertsvitaminKepoxidetovitaminK
[5]. Vitamin K is an essential cofactor for post-translational
gamma-carboxylation, which is required for the maturation
of vitamin K-dependent clotting factors [6]. A single
functional SNP in the promoter of the VKORC1 gene,
VKORC1 c.-1639G>A, affecting VKORC1 gene expression,
has been shown to be a major determinant of coumarin dose
variability, accounting for 13–4 9 %o fd o s er e s p o n s e[ 7–9].
Two common allelic variants of cytochrome P450 2C9,
CYP2C9*2 and CYP2C9*3, which are associated with a
markedly reduced capacity of CYP2C9 to metabolise
coumarins (and thus extended plasma half-life), have also
been shown to influence coumarin dose requirements [6].
Genotype-guided dosing has received increasing
attention as a potentially useful strategy to improve the
efficacy and safety of coumarins. Pharmacogenetically-
guided dosing formulas have been developed to predict
the coumarin maintenance dose [10, 11]. Most of these
studies focussed on warfarin, the most widely used
coumarin worldwide. However, dose prediction models
developed for warfarin are not applicable to phenprocoumon,
a coumarin derivate preferentially used in some European
countries [12]. Phenprocoumon differs from warfarin in both
pharmacokinetic and pharmacodynamic aspects [13]. While
warfarin is predominantly metabolised by CYP2C9, this
enzyme plays a less significant role in the clearance of
phenprocoumon,asthissubstanceisalternativelymetabolised
by CYP3A4, and a significant proportion of unchanged
phenprocoumon is excreted renally [12, 14, 15]. Moreover,
several studies reported an impact of SNPs in genes of other
vitamin K cycle components, e.g. calumenin (CALU),
CYP4F2, microsomal epoxide hydrolase 1 (EPHX1), factor
VII (F7), γ-glutamyl carboxylase (GGCX) and protein C
(PROC), on warfarin dose response [16–28]. Data
concerning the effects of these genes on phenprocoumon
maintenance dose requirements are very limited [29].
Therefore, the aim of our study was to investigate the
impact of SNPs in these genes (VKORC1 c.-1639G>A,
CYP2C9 *2, CYP2C9 *3, CYP4F2 c.1297G>A, CALU c.
*4A>G, EPHX1 c.337T>C, F7 c.-402G>A, F7
c.-401G>T, GGCX c.214+597G>A, PROC c.-228C>T
and PROC c.-215G>A) on the phenprocoumon steady-
state dose and to develop a formula to predict the effective
phenprocoumon maintenance dose. Because the effect of
genetic variants on the pharmacodynamics and pharmaco-
kinetics might differ, we also investigated the effect of
SNPs in these genes on total phenprocoumon plasma
concentrations.
Materials and methods
Outpatients with a stable maintenance phase of phenpro-
coumon therapy were recruited over a period of 15 months
from the anticoagulation clinic of the Division of Angiology
and Haemostaseology ofthe University Hospital ofFrankfurt,
Germany. A target INR range of 2.0–3.0 was the prerequisite
for study participation. Stable maintenance phase was defined
as ≤25% change in phenprocoumon weekly dose to reach the
target INR range ±10% for at least three consecutive
anticoagulation clinic visits with at least 14 days between
subsequent visits. A total of 75 patients aged 19–92 years
were included. Information on age, sex, weight, height,
smoking habits, alcohol consumption, indication for
anticoagulation, and concomitant medication including
alternative agents were collected by a standardised
questionnaire. Data regarding phenprocoumon doses
were obtained from medical records and patients’
phenprocoumon identification cards. Non-fasting venous
blood samples were taken between 7:30 and 9:00 a.m.
for the determination of the international normalised ratio
(INR), plasma concentrations of phenprocoumon, and for
DNA analysis. All patients were advised to take the total
daily phenprocoumon dose in the evening. The study
was approved by the local ethics committee, and all
patients gave their written informed consent to partici-
pate in the study.
Laboratory methods
Blood was collected into Sarstedt Monovette tubes (Sarstedt,
Nümbrecht, Germany) in 0.1 volume 0.106 mol/l trisodium
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measurement of phenprocoumon concentrations, the blood
was collected into Sarstedt Monovette tubes containing
1.6 mg/ml EDTA. Plasma from citrate- and EDTA-
anticoagulated blood samples was prepared by centrifugation
at 2,500×g for 15 min within 0.5 h of the blood draw. The
INR was determined using the thromboplastin reagent STA
Neoplastin Plus (Roche, Mannheim, Germany) on the
automated coagulation analyser STA (Roche) within 1 h of
the blood draw. For determination of the phenprocoumon
plasma concentration plasma aliquots were immediately
frozen and stored at −70°C until assay performance in series.
Total phenprocoumon plasma concentrations were deter-
mined after precipitation with hexobarbitone as the internal
standard, using liquid chromatography coupled with time-
of-flight mass spectrometry. Fifty microlitres of EDTA
plasma were precipitated and vortexed with 200 μlo f
acetonitrile containing hexobarbitone (2.5 ng/μl). After
centrifugation, the supernatant was transferred into auto-
sampler vials. The analysis of 2 μl was performed using an
Agilent 1100 series liquid chromatograph interfaced to an
Agilent 1100 series oa-TOF system (Waldbronn, Germany)
operated in negative electrospray ionisation mode (ESI)
with 10 L/min nitrogen flow at 350°C and 3 kV capillary
voltage. Data acquisition was performed in a mass range
from m/z 100 to 1,100 with simultaneous internal mass
calibration in each recorded spectrum (system reference
mixture supplied by the Agilent dual-sprayer interface, m/z
112.9856 and m/z 1033.9881). Chromatographic separation
was achieved on a 100 × 2.0-mm Polaris C18-Ether 3-μm
column (Varian, Darmstadt, Germany) at 50°C using a
gradient of acetonitrile/0.05% acetic acid (30% acetonitrile
for 0.5 min and increased to 85% in 3.5 min followed by
100% wash and re-equilibration) at 0.4 ml/min over a total
run time of 10 min. Identification of phenprocoumon was
based on retention time and confirmation of accurate
phenprocoumon mass with at least two isotopes (±3 ppm).
For the quantitative assay, a linear calibration curve was
prepared from phenprocoumon spiked into drug-free
plasma over the range of therapeutic concentrations (up to
5 mg/l) [30]. The within- and between-day precisions at the
lower limit of quantitation (0.5 mg/l), at 1 mg/l and 5 mg/
l were less than 7% (n=6 each).
Genetic analyses
Genomic DNAwas prepared from buffy coats of the EDTA
blood samples by standard procedures. DNA samples were
analysed for SNPs (see Table 2) in the genes VKORC1,
CYP2C9, CALU, EPHX1, F7 and GGCX as described in a
separate publication [31]. Amplification of the genes of
PROC and CYP4F2 were performed in a similar manner,
except that an annealing temperature of 60°C was used.
Genotyping for the CYP4F2 c.1297G>A polymorphism in
exon 11 and the PROC c.-228C>T and PROC c.-215G>A
promoter polymorphisms was performed by sequencing
with the following primers: CYP4F2,f o r w a r d5 ’-
GTCTCCTGGGTAGGAAGAG-3’, reverse 5’-
GTTGTGTGTGTCTTTGAG-3’, PROC, forward 5’-GGG
GCTAAAATGAGACCACA-3’,r e v e r s e5 ’-AGGCC
TCCCTCTCCATAGAC-3’.
Definitions
The daily phenprocoumon dose was calculated by the
weekly phenprocoumon dose before blood collection
divided by 7. The body mass index (BMI) was calculated
from each patient’s self-reported height and weight (kg/m
2).
The body surface area (BSA) was calculated using the
formula 0.007184 × height in cm
0.725 × weight in kg
0.425.
According to their product information, drugs were cat-
egorised into drugs not known to interfere with phenpro-
coumon, drugs that potentiate and drugs that attenuate
phenprocoumon pharmacokinetics. According to concomi-
tant drug use, patients were categorised as:
1. Patients not using concomitant drugs
2. Patients using only drugs not known to interfere with
phenprocoumon
3. Patients using potentiating but no attenuating drugs
4. Patient using attenuating drugs but no potentiating
drugs
5. Patients using both potentiating and attenuating drugs
Based on the reports of the frequency of alcohol intake per
week, alcohol consumption was classified into four cate-
gories: no report of alcohol habits, 0–1, 2–5 and >5 drinks
per week.
Statistical analysis
The Kolmogorov–Smirnov and Shapiro–Wilk tests were
used to test variables for normality. Square root transfor-
mation of variables with a skewed distribution was
performed to allow the application of parametric tests and
regression analysis. Analyses of variance (ANOVA) and
Student’s t tests were used to compare the daily phenpro-
coumon doses and phenprocoumon plasma concentrations
among the different groups. Pearson’s or Spearman’s
correlation analysis was performed to estimate the associ-
ation between age, weight, height, BMI and BSA with
regard to the daily phenprocoumon doses and phenprocou-
mon plasma concentrations. Multivariate linear regression
analysis was performed to determine predictors of daily
phenprocoumon doses and phenprocoumon plasma con-
centrations. Variables with a p value<0.1 in the univariate
analysis were entered into a stepwise multiple regression
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pharmacogenetic variables and the frequency of alcohol
consumption in the multiple regression analysis. Continuous
variables were used for age, height, weight, BMI and BSA.
Based on the regression equation, we calculated the
predicted daily phenprocoumon dose for each patient and
compared it with the actual recorded mean daily phenpro-
coumon dose. The association between the actual and
calculated phenprocoumon doses was evaluated using
Passing–Bablok regression analysis.
Based on the present sample size, the study had 80%
statistical power to detect a difference of 0.43 mg between
the actual and the predicted daily phenprocoumon dose,
using a two-sided one-sample t test at the 0.05 significance
level.
The software PASW Statistics 18 for Windows was used
for all statistical analyses. Sample size calculation was
performed with SPSS Sample Power 2.0. Values are given
as the median and range or interquartile range, if not
otherwise stated. A two-tailed p value<0.05 was considered
statistically significant. For practical reasons, in the tables
and figures, the raw data instead of the square root
transformed values are shown. In the figures, p values for
the comparison between groups were calculated with the
Mann–Whitney U test.
All SNPs were tested for deviations from the Hardy–
Weinberg equilibrium using Fisher’s exact test (http://ihg2.
helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl).
Results
The patient cohort was predominantly comprised of
Caucasian patients, as is representative for this region.
Females comprised 50.7% of study participants, and the
most common indication for phenprocoumon therapy
was a history of venous thromboembolism. Because most
of the patients were referred to our centre due to severe
or recurrent venous thromboembolism, the majority of
patients (87%) were on long-term anticoagulation
(≥1 year). Table 1 shows the baseline characteristics of
the study population. Table 2 gives the allele frequencies
of the investigated SNPs. All SNPs were in Hardy-
Weinberg equilibrium (all p>0.07).
Phenprocoumon dose
The median daily phenprocoumon dose in the whole study
cohort was 2.14 mg/day with a wide inter-individual range
(0.75–4.50 mg/day). The daily phenprocoumon dose was
significantly associated with VKORC1 c.-1639, EPHX1
c.337 and PROC c.-228 genotype (Table 3). The largest
dose differences were observed among VKORC1 genotypes
(Fig. 1a). Compared with VKORC1 c.-1639GA carriers, the
median daily phenprocoumon dose was 27.5% less in AA
carriers and 44.6% higher in GG carriers. The phenprocou-
mon dose requirement was also negatively correlated with age
Table 1 Baseline characteristics of the study population. Values are
given as median (range) unless stated otherwise
Parameter Value
Number of patients, n 75
Caucasian, n (%) 73 (97.3)
Black, n (%) 2 (2.7)
Female, n (%) 38 (50.7)
Age, years 64 (19–92)
BSA, m
2 1.88 (1.44–2.75)
Height, cm 170 (151–198)
Weight, kg 76 (49–145)
BMI 26 (18–40)
INR 2.5 (1.8–3.25)
Daily phenprocoumon
dose, mg/day
2.14 (0.75–4.50)
Total phenprocoumon plasma
concentration, mg/l
1.93 (0.72–5.10)
Nicotine habits
a
User, n (%) 9 (12.2)
Non-user, n (%) 65 (87.8)
Alcohol consumption
Patients not reporting alcohol habits 19 (25.3)
0–1 drink per week, n (%) 22 (29.3)
2–5 drinks per week, n (%) 22 (29.3)
>5 drinks per week, n (%) 12 (16.0)
Concomitant medication
Patients with no concomitant drugs 21 (28.0)
Patients using only drugs not
known to interfere with phenprocoumon
b
10 (13.3)
Patients using potentiating
c but
no attenuating drugs
28 (37.3)
Patients using attenuating
d but
no potentiating drugs
2 (2.7)
Patients using both potentiating
and attenuating drugs
14 (18.7)
Indication for anticoagulation, n (%)
Venous thromboembolism
e 50 (66.7)
Atrial fibrillation
e 11 (14.7)
Heart valve replacement
e 4 (5.3)
Other or multiple indications
e 10 (13.3)
BSA = body surface area; BMI = body mass index; INR =
international normalised ratio
a n=74
be.g. captopril, atenolol
ce.g. amiodarone, simvastatin, L-thyroxin, allopurinol
d e.g. metformin, digitoxin, prednisolone
eTarget INR range of 2.0–3.0
374 Eur J Clin Pharmacol (2011) 67:371–381(r=−0.324, p=0.005). Figure 2 illustrates that the median
daily phenprocoumon dose was especially decreased during
the 8th and 9th decade of life (median/range: 1.71/1.50–2.36
and 1.50/0.83–2.14 respectively vs 2.79/1.82–3.64 mg/day
in individuals aged 19–50 years). The association between
phenprocoumon dose requirements and height did not reach
significance in the univariate analysis (p=0.064).
Body weight (p=0.309), BMI (p=0.995), BSA (p=
0.157), CYP2C9, CYP4F2 c.1297, CALU c.*4, F7 c.-402,
F7 c.-401, GGCX c.214+597, PROC c.-215 genotype,
gender, smoking and alcohol habits, or concomitant
medication did not significantly impact on phenprocoumon
dose requirements (Table 3).
Combining VKORC1 c.-1639 genotype, height and age
in the multiple linear regression analysis produced the best
model for phenprocoumon dose prediction, explaining
48.6% of the daily phenprocoumon dose variability
(Table 4).
The final dosing formula for the calculation of the daily
phenprocoumon dose was: √daily phenprocoumon dose
(mg) =0.460+0.238 (VKORC1 c.-1639GG) − 0.271
(VKORC1 c.-1639AA) + 0.007 (height in cm) − 0.004
(age in years). In this regression equation, VKORC1
c.-1639AA and VKORC1 c.-1639GG were coded as 0 if
absent and 1 if present. Because the dosing equation
computes the square root of the daily phenprocoumon
dose, the output must be squared to calculate the actual
daily dose.
To estimate the predictive value of the dosing formula,
we recalculated the daily phenprocoumon dose for each
patient according to the regression equation (Fig. 3). The
Passing–Bablok regression analysis indicated good corre-
lation between the actual and the estimated daily phenpro-
coumon dose (r=0.701, Fig. 3).
Phenprocoumon concentration
The median phenprocoumon concentration in the entire
cohort was 1.93 mg/l and varied between 0.72 and 5.10 mg/
l( F i g .1b). Of the different investigated SNPs, only
VKORC1 and CYP2C9 genotypes were significantly asso-
ciated with total phenprocoumon concentrations (Table 3).
VKORC1 c.-1639A allele carriers were those with the
lowest phenprocoumon concentrations, whereas CYP2C9
variant allele status was associated with higher total
phenprocoumon plasma concentrations (Table 3).
There was a significant association between phenpro-
coumon concentrations and alcohol habits (p=0.020) and a
significant negative correlation between phenprocoumon
concentrations and weight (r=−0.259, p=0.025) and BMI
(r=−0.252, p=0.029). The association between phenpro-
coumon concentrations and age (r=−0.226, p=0.051) and
Table 2 Allele frequencies of the investigated SNPs in the study cohort
Gene Location cDNA position Amino acid
position
Ref. SNP
number (rs)
Allele
frequency
VKORC1 Promoter c.-1639G>A – rs9923231 G 0.62
A 0.38
CYP2C9 Exon 3 c.430C>T p.Arg144Cys rs1799853 C 0.87
T 0.13
Exon 7 c.1075A>C p.Ile359Leu rs1057910 A 0.94
C 0.06
CYP4F2 Exon 11 c.1297G>A p.Val433Met rs2108622 G 0.73
A 0.27
CALU 3`UTR c.*4A>G – rs1043550 A 0.65
G 0.35
EPHX1 Exon 3 c.337T>C p.Tyr113His rs1051740 T 0.66
C 0.34
F7 Promoter c.-402G>A – rs762637 G 0.83
A 0.17
F7 Promoter c.-401G>T – rs7981123 G 0.84
T 0.16
GGCX Intron 2 c.214+597G>A – rs12714145 G 0.57
A 0.43
PROC Promoter c.-228C>T – rs1799808 C 0.67
T 0.33
PROC Promoter c.-215G>A – rs1799809 G 0.46
A 0.54
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factors and concomitant medication. Values are given as median (interquartile range)
Parameter n Daily phenprocoumon dose, mg p value* Phenprocoumon concentration, mg/l p value*
VKORC1 c.-1639
GG 30 2.79 (2.14–3.70) 2.29 (1.98–2.91)
GA 33 1.93 (1.50–2.47) 1.85 (1.53–2.28)
AA 12 1.40 (1.18–1.66) <0.001 1.05 (0.86–1.24) <0.001
CYP2C9
*1/*1 48 2.14 (1.50–2.79) 1.84 (1.27–2.27)
*1/*2 18 1.71 (1.50–2.47) 2.02 (1.60–2.63)
*1/*3 8 2.25 (1.64–3.81) 2.00 (1.83–3.04)
*2/*2 0 ––
*2/*3 1 2.14 (2.14) 5.1 (5.1)
*3/*3 0 – 0.795 – <0.001
CYP4F2 c.1297
GG 37 2.36 (1.71–3.11) 2.06 (1.51–2.56)
GA 36 1.82 (1.50–2.52) 1.84 (1.52–2.26)
AA 2 1.82 (1.50–1.82) 0.221 1.86 (1.45–1.86) 0.472
CALU c.*4
AA 28 2.14 (1.55–2.79) 1.92 (1.27–2.26)
AG 41 2.14 (1.50–2.79) 1.99 (1.53–2.44)
GG 6 2.90 (2.17–3.75) 0.197 1.90 (1.54–3.25) 0.735
EPHX1 c.337
TT 35 2.25 (1.71–3.00) 1.92 (1.56–2.30)
TC 29 2.14 (1.56–2.79) 1.99 (1.49–2.49)
CC 11 1.71 (1.39–2.14) 0.033 1.62 (1.17–2.48) 0.767
F7 c.-402
GG 53 2.14 (1.5–2.79) 1.87 (1.52–2.44)
GA 20 2.14 (1.55–3.16) 1.93 (1.33–2.30)
AA 2 2.04 (1.71–2.04) 0.891 1.92 (1.81–1.92) 0.870
F7 c.-401
GG 50 2.20 (1.66–3.05) 1.91 (1.53–2.42)
GT 25 1.93 (1.50–2.47) 1.95 (1.49–2.32)
TT 0 – 0.193 – 0.367
GGCX c.214+597
GG 26 2.14 (1.66–2.63) 2.01 (1.55–2.34)
GA 34 2.14 (1.50–2.84) 1.93 (1.50–2.52)
AA 15 2.25 (1.61–3.21) 0.835 1.82 (1.47–2.30) 0.808
PROC c.-228
CC 32 2.36 (1.93–3.16) 2.09 (1.66–2.48)
CT 36 1.71 (1.50–2.79) 1.86 (1.39–2.17)
TT 7 1.50 (1.18–2.14) 0.018 1.61 (0.74–2.64) 0.275
PROC c.-215
GG 16 2.79 (1.77–3.56) 1.93 (1.58–2.54)
GA 37 2.14 (1.50–2.68) 1.95 (1.50–2.38)
AA 22 1.71 (1.50–2.47) 0.072 1.90 (1.48–2.40) 0.939
Sex
Female 38 2.14 (1.71–3.00) 2.09 (1.82–2.65)
Male 37 2.14 (1.50–2.79) 0.735 1.65 (1.29–2.22) 0.008
Alcohol consumption
Patients not reporting alcohol habits 19 2.14 (1.50–2.36) 1.61 (1.17–2.15)
0–1 drinks per week 22 2.04 (1.47–3.11) 1.90 (1.50–2.48)
2–5 drinks per week 22 2.68 (1.88–3.40) 2.29 (1.76–3.09)
>5 drinks per week 12 1.82 (1.55–2.33) 0.060 1.72 (1.49–2.07) 0.020
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cance in the univariate analysis. No correlation was observed
between phenprocoumon concentrations and height (p=
0.517), nicotine habits and concomitant medication (Table 3).
The difference in phenprocoumon concentrations between
women and men (Table 3) seemed to be due to the higher
BMI values in men (BMI median/range: men 27/21-37,
women: 25/18-40, p=0.019) because sex was not indepen-
dently associated with phenprocoumon concentrations in the
multivariate analysis.
In the multiple linear regression analysis, the VKORC1
c.-1639 and CYP2C9 genotype, age, and the square root of
BMI were independently and significantly associated with
the phenprocoumon plasma concentrations (Table 5).
Comparable to the daily phenprocoumon dose, the
VKORC1 genotype was found to be the most powerful
predictor of phenprocoumon plasma concentrations, account-
ing for 38.3% of the observed inter-individual variability in
phenprocoumon plasma concentrations (Table 5). The full
model explained 52.8% of the variance of the phenprocou-
mon concentration (Table 5).
Discussion
In this study, we evaluated clinical parameters along with
SNPs in eight genes including VKORC1, CYP2C9,
CYP4F2, CALU, EPHX1, F7, GGCX and PROC to identify
factors determining the total phenprocoumon plasma
concentrations and phenprocoumon maintenance dose
requirements in patients on stable phenprocoumon therapy.
About 53% of the variability of the total phenprocoumon
concentration and 49% of the phenprocoumon dose
variability could be explained by a pharmacogenetically
based model. The largest part of variance was captured
solely by VKORC1 c.-1639, which accounted for approx-
imately 38% of the variability of the plasma concentration
as well as the daily phenprocoumon dose. This is in line
Table 3 (continued)
Parameter n Daily phenprocoumon dose, mg p value* Phenprocoumon concentration, mg/l p value*
Nicotine habits
Smoker 9 1.93 (1.50–3.00) 1.53 (1.13–2.13)
Non-smoker 65 2.14 (1.56–2.79) 0.485 1.95 (1.58–2.39) 0.124
Concomitant medication
No concomitant drugs 21 2.14 (1.71–3.16) 2.15 (1.50–2.94)
Drugs not known to interfere with phenprocoumon 10 2.47 (1.66–3.05) 1.63 (1.50–2.24)
Potentiating drugs, no attenuating drugs 28 1.82 (1.50–2.52) 1.92 (1.19–2.30)
Attenuating drugs, no potentiating drugs 2 1.77 (1.39–1.77) 2.06 (1.85–2.06)
Both potentiating and attenuating drugs 14 2.31 (1.66–3.54) 0.380 1.93 (1.72–2.47) 0.346
*p values for the overall comparison among the subgroups
p<0.001 
p<0.001 
p<0.001 
p<0.001 
a
b
Fig. 1 a Daily phenprocoumon doses according to VKORC1 c.-1639
genotypes. The median daily phenprocoumon doses are depicted
within the boxes. b Phenprocoumon plasma concentrations according
to VKORC1 c.-1639 genotypes. The median daily phenprocoumon
plasma concentrations are depicted within the boxes. In a and b the
boxes end at the 25th and 75th percentiles. The whiskers extend to the
farthest points that are not outliers. Outliers are depicted as open dots
Eur J Clin Pharmacol (2011) 67:371–381 377with similar findings of the role of VKORC1 in other
coumarins such as warfarin and acenocoumarol [8, 9, 32,
33].
We did not detectaneffectofCYP2C9 on phenprocoumon
maintenance doses. This is in accordance with the studies of
Hummers-Pradier et al. [34] and Visser et al. [35], who
found no association between CYP2C9 variant alleles and
phenprocoumon maintenance dose requirements in 185 and
173 outpatients respectively. However, Schalekamp et al.
observed a 3.7-mg lower weekly phenprocoumon steady-
state dose for CYP2C9*2 carriers and a 4.4-mg lower weekly
dose for CYP2C9*3 carriers compared with wild-type
carriers [36]. These differences may be due to the larger
cohort (n=284) with a higher number of CYP2C9 *2 and
especially *3 carriers in their study [36].
Somewhat surprising was the finding that CYP2C9
haplotypes affected the phenprocoumon plasma concen-
trations. Pharmacokinetic factors such as the CYP2C9
genotype are expected to alter the dose requirements, but
not the plasma levels necessary to provide a therapeutic
INR. However, we measured the total concentration of
plasma phenprocoumon that might not be linearly translated
into INR values. It would be interesting to see whether the
concentrations of unbound phenprocoumon and S-
phenprocoumon, which has a higher anticoagulant potency
than the R-enantiomer [12], are also associated with the
CYP2C9 genotype.
We did not find a substantial role for the gene variants
CYP4F2 c.1297G>A, CALU c.*4A>G, EPHX1 c.337T>C,
F7 c.-402G>A, F7 c.-401G>T, PROC c.-228C>T and
PROC c.-215G>A as determinants of total phenprocoumon
plasma concentrations or phenprocoumon dose variability.
The inclusion of these SNPs into the regression equation
for estimation of daily phenprocoumon doses did not
improve the predictive value of this model.
In contrast, clinical factors such as age, height and BMI
significantly contributed to the variability of phenprocou-
mon doses and phenprocoumon plasma concentrations
p=0.009 
p=0.011  p=0.312 
p=0.169 
Fig. 2 Daily phenprocoumon
doses in different age groups.
Median doses are depicted
within the boxes. The boxes end
at the 25th and 75th percentiles.
The whiskers extend to the
farthest points that are not
outliers. Outliers are depicted as
open dots
Table 4 Model of best fit in multiple linear regression analysis for mean daily phenprocoumon doses. Prior to analysis, square root transformation of
daily phenprocoumon doses was performed. Dummy variables were created for VKORC1 genotypes with VKROC1 c.-1639GA as the reference group
Genotype R
2 after entry, % Adjusted R
2 * after entry, % Regression coefficient in final model p value in final model
Intercept 0.460
VKORC1 c.-1639GG 30.3 0.238 <0.001
VKORC1 c.-1639AA 39.3 37.6 −0.271 <0.001
Height 47.3 45.0 0.007 0.004
Age 51.4 48.6 −0.004 0.018
Regression equation for estimating daily phenprocoumon dose: √daily phenprocoumon dose (mg) =0.460+0.238 (VKORC1 c.-1639GG) − 0.271
(VKORC1 c.-1639AA)+0.007 (height) − 0.004 (age)
378 Eur J Clin Pharmacol (2011) 67:371–381respectively. Age is a well-known predictor of coumarin
dose response [11]. In our study, patients with ages 51–70,
71–80 and 81–92 years needed 23.3%, 38.7% and 46.2%
lower daily phenprocoumon doses compared with younger
patients. Concomitant medication and the resulting increased
riskofdruginteractionsmight predisposethe elderlytohigher
coumarin sensitivity [37]. However, although the number of
concomitant drugs was high in our study cohort, especially
in the elderly (e.g. 52.6% of patients with ages of 71–
80 years had ≥5 drugs), age was the only independent
predictor of total plasma phenprocoumon concentrations and
phenprocoumon dose requirements.
Thepotentialofdrugstointerferewithcoumarinsismainly
attributed to their interaction with the cytochrome P450
system [38]. The lack of association between concomitant
medication and phenprocoumon might be due to its lower
susceptibility to CYP2C9 inhibitors because CYP3A4 is also
involved in its metabolism [15]. However, the categorisation
of concomitant drug use in our study was rather crude, as we
did not consider drug dosage and the potency of various
drugs to interfere with phenprocoumon. It cannot be
excluded that concomitant drugs are more relevant in other
study populations with a higher number of patients on
CYP3A4 substrates such as statins or potent CYP3A4
inhibitors, e.g. amiodarone. In our study, 15 patients were
taking a statin, and 4 patients were taking amiodarone.
Because of the above observations, our final dosing
equation for the prediction of the daily phenprocoumon
dose was restricted to VKORC1, age and height, as these
parameters alone accounted for 48.6% of daily phenpro-
coumon dose variability. A pharmacokinetic–pharmacody-
namic model that incorporated the effects of VKORC1 c.-
1639, CYP2C9, age and BMI explained 52.8% of the drug
plasma concentration variability.
The explanation of 50% of the total variability of the daily
phenprocoumon maintenance dose is not sufficient to predict
the exact maintenance dose in the individual patient.
However, dosing equations such as those presented in this
paper may help to identify subjects requiring low, intermedi-
ate, or high daily phenprocoumon doses. Pharmacogenomic-
based dosing equations could reduce the time needed to find
the adequate individual daily phenprocoumon dose and might
help to avoid over-anticoagulation, especially in the early
phase of phenprocoumon therapy. Moreover, pharmacoge-
nomics might help to identify subjects more susceptible to
drug interactions with phenprocoumon.
Our study is underpowered to detect factors with only a
minor effect on phenprocoumon dose variability. However,
our results are in line with genome-wide association studies
that showed that VKORC1 and CYP2C9 may be considered
the main pharmacogenetic predictors of coumarin dose
requirements and demonstrated that common SNPs with
substantial effects on coumarin dose requirements are
unlikely to be discovered outside of the VKORC1 and
CYP2C9 genes [39, 40]. More sophisticated models
integrating a large number of SNPs and other factors with
minor influence might be necessary for the exact prediction
of phenprocoumon maintenance doses, but might not be
feasible and cost-effective in clinical routine. Thus, a
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Fig. 3 Passing–Bablok regression for the calculated and actual daily
phenprocoumon doses. The solid line is the line of regression, the
dotted line is the line of identity
Genotype R
2 after
entry, %
Adjusted R
2*
after entry, %
Regression coefficient
in final model
p value in
final model
Intercept 3.968
VKORC1 c.-1639GG 29.6 0.509 0.001
VKORC1 c.-1639AA 40.0 38.3 −0.690 <0.001
Age 46.2 43.9 −0.009 0.038
CYP2C9*3 49.4 46.5 0.507 0.012
CYP2C9*2 53.3 49.9 0.366 0.014
√BMI 56.6 52.8 −0.321 0.026
Table 5 Model of best fit in
multiple linear regression
analysis for phenprocoumon
plasma concentrations. Dummy
variables were created for
VKORC1 genotypes (VKROC1
c.-1639GA = reference group)
and CYP2C9 (CYP2C9*1/*1 =
reference group)
Eur J Clin Pharmacol (2011) 67:371–381 379combination of standardised protocols for the start-up
phenprocoumon therapy with crude estimations of the
presumed maintenance doses based on relatively few
parameters might be a pragmatic solution to the problem.
Our study has several limitations. We applied the
prediction formula to all patients and showed a good
correlation between the estimated and the given mainte-
nance dose. However, no data from an independent
prospective study were available to validate our dosing
formula.
Recruiting only patients with stable phenprocoumon
doses might have excluded a substantial subgroup of
patients. However, the definition of stable maintenance
doses in our study was a bit more liberal compared with
other studies [19, 21]. The inclusion of patients with
unstable phenprocoumon doses would have increased the
interindividual dose variability and has the potential to
reduce the predictive value of regression models.
In our study, 25% of patients did not report on alcohol
habits. Data on alcohol consumption from questionnaires
may be unreliable as patients with heavy alcohol consump-
tion might prefer not to report their drinking habits. Adding
biomarkers such as carbohydrate-deficient transferrin or
phosphatidylethanol to in-depth interviews might have been
better tools to classify alcohol consumption [41, 42].
Despite the fact that many dosing equations have been
developed to predict warfarin dose requirements, the benefit
of pharmacogenetic-guided coumarin therapy remains a
matter of controversy [43]. Some studies indicate that early
INR and standardised dose adaptation can cover for the
genetic information, which is mainly only significant in the
early phase of therapy [44, 45]. The impact of genotype-
guided dosing formulas might differ among coumarins with
markedly different pharmacokinetic characteristics. Our
study provides a rationale for a rough prediction of
phenprocoumon maintenance doses. Prospective clinical
trials are warranted to investigate whether genotype-guided
dosing formulas are superior to standardised dosing proto-
cols for improved safety and cost-effectiveness of coumarin
therapy.
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